Amarin Touts Positive Data For Its Heart Disease Drug In Current/Former Smokers

Amarin Corporation plc AMRN announced that new REDUCE-IT data show that Vascepa/Vazkepa (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking.
In this post hoc exploratory analysis, icosapent ethyl (IPE) treatment significantly reduced the risk of first and total primary composite events in current/former smokers by 23% and in former smokers by 29%, compared to the placebo.
Related: Amarin's New Vascepa Data Shows Significant Reduction In Heart Attack Subtypes.
IPE treatment reduced the incidence of CV events in current smokers by 23.8% and former smokers by 23.0% to levels observed in never smokers (25.7%) in the placebo group.
Compared with placebo, IPE use in combined current and former smokers was associated with significant reductions in first primary composite events and total primary composite events.
Overall, there were similar estimated rates of first occurrences of CV death, MI, stroke, coronary revascularization, or hospitalization for unstable angina in current smokers (23.8%) and former smokers (23.0%) assigned to IPE compared to the placebo (25.7%).
Price Action: AMRN shares closed lower by 2.31% at $1.27 on Friday.